### Supplemental Table S4: 5-years lung metastasis free survival (LuMFS).

|                  | Univariate | Multivariate* | Multivariate** |
|------------------|------------|---------------|----------------|
|                  | P          | HR            | 95.0% CI for HR | P          | HR            | 95.0% CI for HR | P          | HR            | 95.0% CI for HR |
|                  |            | Lower | Upper |            |            | Lower | Upper |            |            | Lower | Upper |
| Age (>50 vs <=50) | 0.144      | 1.638 | 0.846 | 3.174 | -         | -     | -     | -         | -         | -     | -     |
| ER (+ vs -)      | <0.001     | 0.25  | 0.125 | 0.498 | -         | -     | -     | -         | -         | -     | -     |
| Grade TMA (3 vs 1-2) | 0.011     | 2.704 | 1.259 | 5.808 | -         | -     | -     | -         | -         | -     | -     |
| Nodule (N+ vs N0) | 0.256      | 1.488 | 0.749 | 2.956 | 0.646     | 1.208 | 0.538 | 2.713    | -         | -     | -     |
| Size (>2cm vs <=2cm) | 0.007     | 2.626 | 1.299 | 5.311 | -         | -     | -     | -         | 0.069     | 2.170 | 0.942 | 4.997 |
| Claudin-2 Continuous | 0.004     | 1.254 | 1.077 | 1.461 | 0.005     | 1.244 | 1.067 | 1.45     | 0.008     | 1.229 | 1.055 | 1.432 |
| Afininax/Continuous | 0.001     | 1.198 | 1.074 | 1.336 | 0.001     | 1.207 | 1.081 | 1.348    | 0.002     | 1.186 | 1.062 | 1.324 |
| Claudin-2 Low-High | 0.096      | 2.163 | 0.872 | 5.368 | 0.100     | 2.146 | 0.864 | 5.326    | 0.093     | 2.183 | 0.878 | 5.423 |
| Afininax Low-High | 0.005      | 3.137 | 1.418 | 6.941 | 0.005     | 3.106 | 1.404 | 6.873    | 0.010     | 2.888 | 1.282 | 6.502 |

Abbreviations: HR, Hazards Ratio; CI, confidence interval; ER, estrogen receptor. Numbers in bold represent statistically significant differences.

*Each marker was added one at the time in the model with clinical parameter (N stage). Results of the clinical parameters were those when associated with Claudin-2 continuous.

**Each marker was added one at the time in the model with clinical parameter (T stage). Results of the clinical parameters were those when associated with Claudin-2 continuous.